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Abstract 
Objectives: Research suggests that ecstasy users exhibit psychobiological changes 
relative to nonusers such as altered sleep patterns and cognitive deficits. In turn, it has 
been suggested that sleep quality may be a mediator of such cognitive deficits in 
ecstasy users. The present study sought to investigate this proposed relationship. 
Methods: Aspects of cognitive functioning in 104 ecstasy users and 103 nonusers 
obtained from our previous studies were reanalysed to explore the extent to which 
ecstasy-related group differences were attributable to differences in sleep quality. 
Cognitive function was assessed via the computation span test, consonant updating, 
paired associate learning, syllogistic reasoning and word fluency. Sleep quality was 
measured via the Epworth Sleepiness Scale (ESS), and the Karolinska Sleepiness 
Scale (KSS). Results: Ecstasy users performed worse than nonusers on all cognitive 
measures. While no differences were observed on the ESS, ecstasy users reported 
greater tiredness at the beginning of testing than nonusers. When the sleep variables 
were included as covariates, the effects of ecstasy on all cognitive measures remained 
significant. Conclusions: The results of the present study suggest little evidence for 
the mediating effects of sleep on cognitive function in ecstasy users.   
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Introduction 
Research from our laboratory has previously demonstrated that ecstasy users 
are impaired on executive function (spatial working memory- Wareing et al. 2004, 
memory updating- Montgomery et al. 2005a, access to semantic memory- 
Montgomery et al. 2005a) and other working memory/executive based tasks 
(associative learning- Montgomery et al. 2005b, syllogistic reasoning- Fisk et al. 
2005; Montgomery et al. 2005c). Similar findings have been observed by other 
authors (see Morgan, 2000, for a review of the literature). Apparent ecstasy-related 
deficits may be mediated by other drug use (Croft et al, 2001; Dafters et al 2004) 
although results from other studies suggest that ecstasy-related deficits remain 
following control for the use of other illicit drugs (Fisk et al, 2004; Reay et al 2006). 
Other potential mediators include lifestyle differences between users and nonusers 
such as exercise intensity, pre-morbid conditions and sleep-related impairments, (Cole 
et al, 2002; Cole & Sumnall, 2003; Huxster et al. 2006). However these have yet to be 
thoroughly explored. 
With regard to the last of these potential mediators, previous research has 
shown that ecstasy users exhibit disturbed sleep patterns. Given that ecstasy users also 
exhibit cognitive deficits, the present study sought to investigate the extent to which 
such cognitive deficits are mediated by degraded sleep in ecstasy users. Primary 
evidence from subjective accounts of ecstasy users suggests that they are aware that 
they have less sleep when using than when not using ecstasy. Baylen and Rosenberg 
(2006) reviewed 24 studies of the acute subjective effects of ecstasy (i.e. occurring 
within 24 hours after use). Of the studies that assessed sleep, a range of between 9-
85% of participants reported “sleeplessness” as a subjective effect of ecstasy. This is 
corroborated in another review where it is reported that the chronic use of ecstasy 
 4 
causes sleep disturbances and sleep deprivation (Montoya et al. 2002). With ecstasy, 
the primary effects on sleep may be similar to those of other amphetamine analogues 
such as MDE; Gouzoulis et al. (1992) administered 140mg of MDE to sleeping 
participants, who awoke 60-120 minutes after administration, and stayed awake for 
150+ minutes (resulting in a significant decrease in total sleep time). While it appears 
logical that disturbance of sleep may be a primary subjective effect of ecstasy due to 
its stimulant like properties, studies in ecstasy users also report that these effects may 
be longer lasting. Parrott et al. (2006) report that 40% of the 209 ecstasy users in their 
study attributed poor sleep when “off drug” to their use of ecstasy. Another recent 
study (Huxster et al. 2006) also found that the “restless sleep” factor of the SCL-90-R 
was elevated in ecstasy users, and users reported sleep disturbances for 48 hours after 
use.  
 Some studies looking at the longer lasting effects have also shown that ecstasy 
use is associated with decreases in sleep time. For example, Allen et al. (1993) 
assessed the sleep of ecstasy users via EEG. Abstinent users of ecstasy were found to 
have significantly less total sleep time, and also significantly less Non-REM sleep, 
which was due to an average of 37 minutes less sleep at stage 2. Contrasting with 
these findings, McCann et al. (unpublished, cited in McCann et al. 2000) found that 
ecstasy users actually have more efficient sleep, with increases in deeper sleep at 
stages 3 and 4 (although the authors state that the differences between this study and 
previous studies may be due to differences in characteristics of the users and their 
drug use).  
 The balance of the evidence set out above indicates that ecstasy users are 
subject to altered sleep patterns and impaired sleep quality. In turn, sleep deprivation 
and sleep disorders have been shown to adversely affect memory (see Maquet, 2001 
 5 
for review). In a review of sleep deprivation studies, Harrison and Horne (2000) 
conclude that performance on tasks that utilise the frontal lobes is greatly affected by 
sleep deprivation. They have also shown that decision-making and reasoning are also 
impaired after one night of sleep loss (Harrison & Horne, 1999). More recently, 
Nilsson et al. (2005) found that after 31 hours sleep-deprivation, participants were 
impaired on the modified six-elements task (a test of executive function). 
Correspondingly, Lieberman et al. (2002) found that following sleep deprivation, 
executive and reaction time measures were all impaired. Compared to the pre-sleep-
deprivation baseline, nearly all measures were degraded: participants’ hits on a 
vigilance task decreased by almost half whereas reaction time increased; all visual 
reaction time measures were impaired, and spatial working memory was also 
significantly impaired (correct responses decreased, reaction time increased and time-
out errors increased). 
 A number of explanations are possible for the ecstasy-related decrement in 
aspects of cognition. It is possible that the cognitive functioning of ecstasy users is 
degraded due to use of the drug, sleep deprivation/restless sleep, or a pre-existing 
cognitive deficit unrelated to ecstasy use. A number of different models of sleep-
ecstasy-cognition interrelationships are possible. Firstly, ecstasy might impair sleep 
directly via psychopharmacological effects and the resulting sleep impairment might 
account for all or some of the observed cognitive deficits. Secondly, lifestyle 
differences might result in a person obtaining less sleep or suboptimal sleep. Such 
individuals might also co-incidentally consume ecstasy but the cognitive deficits 
associated with sleep impairment are a consequence of selecting a lifestyle which is 
characterised by less sleep and not due to ecstasy. Accordingly one study found that 
regular ecstasy users attributed their cognitive deficits to reduced sleep rather than 
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their use of ecstasy (Topp et al. 1999) and as summarised above, sleep deprivation 
impairs cognitive performance. Thirdly, it may be that ecstasy adversely affects 
cognition and sleep but the two effects are entirely unrelated. 
Fortuitously, we have collected data on aspects of sleep quality throughout our 
programme of research, although for the most part we have yet to analyse this data. 
By pooling the data obtained in our previous research we are able to build up a large 
sample allowing us to more adequately investigate differences in sleep attributes 
between ecstasy users and nonusers and to investigate the potential mediating role of 
these in accounting for ecstasy-related deficits in other aspects of cognition. By way 
of summary, it was expected that ecstasy-related differences in sleep quantity and 
quality would mediate deficits in aspects of cognition including executive 
functioning, learning and reasoning.  
 
Method 
Participants.   
In total, 207 individuals completed the Epworth Sleepiness Scale (ESS). There 
were 104 ecstasy users and 103 nonusers. Participants were initially recruited through 
direct approach to Liverpool John Moores University undergraduate students, 
including psychology majors and psychology-biology joint students. Subsequently, 
word of mouth referral was used with most participants being recruited by this means. 
Background data for each group are set out in Tables 1 and 2.  
<<Insert Tables 1 and 2 about here>> 
Measures 
Measures of Daytime Sleepiness 
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The ESS represents the likelihood of dozing off during the day in various 
situations. Its validity and reliability as a measure of daytime sleepiness are well 
established (see for example, Chen et al, 2002; Johns, 1992; Johns, 2000; Vignatelli et 
al, 2003; Violani et al, 2003) with scores exceeding 10 indicative of some form of 
sleep disorder (Johns & Hocking, 1997). The ESS contains eight items, which a 
participant has to score on a scale of 0 (would never doze off in this situation) to 3 
(high chance of dozing off in this situation). A total score over all eight items was 
used in the present analysis, with higher scores indicative of increased subjective 
daytime sleepiness. 
 The Karolinska Sleepiness Scale (KSS) measures the participant’s state of 
sleepiness at a given moment in time. Participants are asked: ‘Use the following scale 
to indicate how sleepy you are feeling at this moment. Write the number in the box.’ 
Nine numerical response alternatives are listed vertically with verbal labels assigned 
to alternate numbers: 1. Extremely Alert; 2 ; 3 Alert; 4 ; 5 Neither Alert Nor Sleepy; 6 
; 7 Sleepy But Not Fighting Sleep; 8 ; 9 Extremely Sleepy, Fighting Sleep, Effort to 
Stay Awake. The participant selects the number which corresponds to their present 
state and writes it in a box situated at the bottom of the page. Thus responses range 
from 1 to 9 with higher numbers indicative of greater sleepiness. The measure was 
administered twice, once at the beginning of testing and a second time at the end of 
the session. The reliability and validity of the KSS as a real-time measure of daytime 
sleepiness are well established (see, for example, Gillberg et al, 1994; 1996; Harma et 
al, 2002). As we began administration of the measure after the start of our research 
programme a somewhat smaller sample, 69 ecstasy users and 63, nonusers completed 
the KSS. Details of this sub-sample may be found in Table3. Likewise, not all 
participants completed the remaining tasks which were administered at different times 
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during our research programme. The number of individuals completing each of the 
cognitive tasks set out below is indicated in Table 4. 
<<Insert Tables 3 and 4 about here.>> 
Executive Function Measures 
 Computation Span. Participants were required to solve a number of arithmetic 
problems (e.g., 4+7 = ?) by circling one of three multiple-choice answers as each 
problem was presented. They were also required to simultaneously remember the 
second digit of each presented problem. At the end of each set of problems the second 
digits had to be recalled in the order in which they were presented. The number of 
arithmetic problems that the participant had to solve, while at the same time 
remembering each second digit, gradually increased as the test proceeded. In order to 
proceed, the participant was required to be correct in at least two of the three trials at 
the current level. Computation span was defined as the maximum number of end 
digits recalled in serial order, with the added requirement that the corresponding 
arithmetic problems had been solved correctly. In order to take account of individual 
differences in the non-executive maintenance component of the task, the load on 
executive resources was computed as the percentage difference between the 
computation and digit span scores. Large percentage differences are indicative of poor 
executive functioning. Data for all of the participants who took part in Fisk et al’s 
(2004) study were included in the present study and further details of the task may be 
found there. 
Consonant Updating: In this computer-based task, the participant was 
presented with a random sequence of between 6 and 12 consonants on a computer 
screen. Twenty-four such lists were presented, and in each case, the participant was 
unaware of the number of consonants to be presented. The task was always to recall 
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the most recent six consonants in the order in which they were presented. The 
participant experienced six trials at each of the four list lengths: 6, 8, 10, and 12 items. 
The order in which the lists were presented was randomised. A single composite score 
of updating was calculated as in Fisk and Sharp (2004).  
Chicago Word Fluency Test. Participants were instructed not to write any 
place names, peoples name or plurals in this test. Firstly participants were given five 
minutes to write down as many words as they could, beginning with the letter “S”. 
Secondly, they were given four minutes to write down as many four-letter words 
beginning with “C” as they could. Scores for both letter fluency tasks were the 
number of appropriate words in each case. In the present study, the two fluency 
measures were standardised and averaged to form a single standardised composite 
measure of letter fluency. 
Semantic Fluency: In the semantic fluency task, participants were required to 
recall as many animal names as they could think of. This could be different species, or 
breeds within species. Participants were given four minutes for this task. The score 
(which was standardised) was the number of appropriate words that were produced. 
Although not an executive function measure semantic fluency was included as a 
control for the letter fluency measure.  
For both the word fluency and consonant updating tasks, data for all of the 
participants who took part in Montgomery et al’s (2005a) study were included in the 
present study and further details of the tasks may be found there. 
The executive function measures used in the present study are established 
indicators of prefrontal executive processes. Computation span has been used 
extensively in the cognitive ageing literature as a measure of executive functioning 
(e.g., Fisk & Warr, 1996; Salthouse & Babcock, 1991) and it is functionally similar to 
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the operation span measure used by Miyake et al (2000) in their study of executive 
processes. Consonant updating has also been employed by Miyake et al and others 
(e.g., Morris & Jones, 1990) as a measure of executive functioning and other 
researchers have demonstrated that these tasks utilise prefrontal executive resources 
(e.g., Collette et al, 2006; van der Linden et al 1999). The Chicago fluency task has 
long been known to load on prefrontal neural processes (Kolb & Whishaw, 1985; 
Parkin & Jarva, 1999; Warkentin & Passant, 1997). 
 
Associative Learning Measures. 
Learning was assessed through a verbal paired associates task. Participants 
were presented sequentially with the same eight word pairs (taken from Fisk, 2003) 
on a computer screen. After each presentation, the participant was prompted with the 
first member of each pair and required to recall the second member. Eight such trials 
were administered. The order of presentation was randomised and changed for each 
trial. Measures included the number of correct responses in trial 1 (a measure of initial 
learning), the number of correct responses subsequently forgotten and the number of 
trials required to learn all associations. Data for all of the participants who took part in 
Montgomery et al’s (2005b) study were included in the present study and further 
details of the task may be found there.  
 
Syllogistic reasoning  
Abstract syllogisms were used, for example, given that:  
Some A are B,  
and 
No B are C 
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Participants were expected to produce the following logical inference:  
Some A are not C.  
Syllogisms vary in difficulty with one-model problems being the easiest and three 
model the hardest. Participants attempted to generate solutions for four one-model 
syllogisms, four three-model syllogisms, and four syllogisms for which there was no 
valid conclusion (NVC, requiring either 2 models or 3 models). There are eight 
possible inferences that can be drawn for the one model problems and four each for 
the NVC and three model problems. The three model and NVC responses were 
combined so as to produce a maximum score of 8 for these more difficult problems.  
The syllogisms were the same as those used by Montgomery et al (2005c) and Fisk 
and Sharp (2002) and further details of the task may be found there. Data for all of the 
participants who took part in Montgomery et al’s (2005c) study were included in the 
present study.  
 
Procedure 
Full procedural details may be found in the original papers cited above. Written 
informed consent was obtained from all participants. Ethical approval was obtained 
form the Ethics Committee of Liverpool John Moores University and the research was 
conducted in accordance with the ethical guidelines of the British Psychological 
Society. 
 
Design 
The ESS was analysed in a between participant design with user group between 
participants (ecstasy users versus nonusers). The KSS was analysed in a mixed design 
with user group between participants and time of administration within participants 
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(participants completed the KSS at the beginning and again at the end of the testing 
session). The measures of cognitive functioning were analysed in a between 
participant design with user group between participants (ecstasy users versus 
nonusers). Subsequently the sleep measures were included as covariates and the 
analyses were repeated to establish the extent to which group-related cognitive 
deficits were mediated by group differences in sleep functioning. The relationship 
between the drug use indices, the sleep measures, and the cognitive outcome variables 
were explored through correlation (Spearman’s rho, ρ). 
 
Results 
 Inspection of Table 1 reveals that for the complete sample, the majority of 
ecstasy users were also current or previous users of cannabis and cocaine. A 
substantial minority had also used amphetamine in the past. Use of other drugs among 
non ecstasy users was rare and largely limited to cannabis. Although many non 
ecstasy users were using cannabis, the typical lifetime cannabis dose and level of 
recent use was far less than that of ecstasy users.  
The indicators of daytime sleepiness are reported in Table 2. The Epworth 
sleepiness scale (ESS) represents the likelihood of dozing off during the day in 
various situations and is thus an indicator of daytime sleepiness. Scores exceeding 10 
are thought to be indicative of some form of sleep disorder. The number of ecstasy 
users exceeding this score numbered 10, with exactly the same number of nonusers 
exceeding it. Thus the prevalence of high scores was identical for users and nonusers. 
Similarly in terms of the median scores, users and nonusers did not differ 
significantly.  
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Although the Karolinska measure utilises a rating scale it is widely treated in 
the research literature as conforming to interval level of measurement (see for 
example, Otmani, et al, 2005; Richter, et al, 2005; Swann et al, 2006; van den Berg et 
al 2005). In the present study, mixed ANOVA was applied with ecstasy user group 
between participants and time of administration as the within participant variable. 
This revealed a significant main effect of time of testing with participants indicating 
greater levels of tiredness on the second occasion of testing, F(1,130) = 31.88, p<.001. 
This was qualified by a significant time by group interaction, F(1,130) = 4.32, p<.05. 
Compared to nonusers, ecstasy users reported higher levels of tiredness at the 
beginning of testing, however, at the second occasion of testing there was little 
difference between the groups. The increase in tiredness between the two occasions of 
testing was greater for nonusers. Users began the session more tired but registered less 
change throughout the session. The main effect of group was non significant, F < 1. 
In order to establish whether the group differences on the sleep quality and 
sleep type measures were responsible for the ecstasy-related deficits in other aspects 
of cognition we repeated our original analyses initially without any covariates and 
subsequently with the sleep measures as covariates. In relation to computation span 
the initial analysis revealed that ecstasy-related decrement was statistically significant, 
F(1,205)=13.88, p<.001, η2 = .063. Following inclusion of the ESS as a covariate, the 
group difference remained statistically significant, F(1,200)=15.16, p<.001, η2 = .070.  
For those participants completing the consonant updating task, nonusers achieved a 
slightly higher score compared to users, F(1,62)=5.44, p<.05, η2 = .081.  For this 
sample, ecstasy users registered significantly higher scores on the ESS. Following 
statistical controls for ESS, the ecstasy-related consonant updating deficit remained 
statistically significant, F(1,60)=5.33, p<.05, η2 = .082.  
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On the composite letter fluency measure, the difference between the 
standardised scores indicates that ecstasy users produced fewer words. ANOVA with 
user group between participants and the semantic fluency score as a covariate 
revealed a statistically significant group difference, F(1,96) = 10.48, p<.01, η2 =098 . 
The effect remained significant following control for the ESS, F(1,94) = 9.11, p<.01, 
η2 =088. 
Ecstasy users were impaired on all aspects of learning. MANOVA with the 
three learning measures as dependent variables revealed that the multivariate effect 
was statistically significant, Λ = 0.852, F(3,89) = 5.15, p<.01. The effect remained 
significant following control for the ESS, Λ = 0.859, F(3,87) = 4.77, p<.01. 
 With regard to syllogistic reasoning, for both the easier one model and the 
more difficult two/three model problems, ecstasy users achieved fewer correct 
responses compared to nonusers. Mixed ANOVA with level of difficulty within 
participants and user group between participants revealed that the group difference 
was statistically significant, F(1,81) = 5.74, p<.05, η2 = .066. The interaction between 
group and level of difficulty failed to reach significance, F(1,81) = 2.15, p>.05. For 
this sample, ecstasy users registered significantly lower scores on the Epworth 
measure indicating a lower prevalence of daytime sleepiness. Following statistical 
controls for the Epworth measure, the ecstasy-related reasoning deficit remained 
statistically significant, F(1,79)=6.68, p<.05, η2 = .078. To summarise, there is no 
evidence that the variance attributable to the ESS mediated the ecstasy/polydrug-
related cognitive deficits that we have observed previously in studies from our 
laboratory.  
With one exception, there were too few participants completing the KSS as 
well as the other cognitive measures reported above, to allow the potentially 
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mediating role of group differences in this variable to be assessed. The exception was 
the computation span measure. The 69 users completing the Karolinska measure 
recorded a percentage processing cost of 43.03 (s.d. = 25.50) on the computation span 
measure compared with a 34.18% (s.d. = 22.93) cost for the 63 nonusers. Following 
control for group differences in the two Karolinska scores, this difference remained 
statistically significant, F(1,128) = 4.47, p<.05, with η2 = .034 virtually unchanged 
from the level prior to inclusion of the covariates. 
It is clear from Table 5 that the ESS was not significantly correlated with any 
of the cognitive measures. With regard to the Karolinska, for the most part, as noted 
above, too few participants completed both it and the cognitive measures so 
correlations with respect to these variables cannot be reported. However with regard 
to the computation span task where the sample size was adequate, correlations 
between this and the Karolinska measures were both near zero (ρ =-.013 and -.017 for 
the beginning and end of testing respectively, p>.05 in both cases). The ESS was 
significantly correlated with the Karolinska sleepiness measure at the second 
administration indicating that those participants who reported more fatigue at the end 
of testing also scored higher on the ESS. 
<<Insert Table 5 about here.>> 
With one exception, the ESS was not significantly correlated with any of the 
drug use measures reported in Table 5. Regarding the exception, higher levels of 
ecstasy use during the 30 days prior to testing were associated with less reported 
daytime sleepiness. In contrast to this, the Karolinska score at the start of testing was 
positively and significantly correlated with lifetime use of ecstasy and cannabis. 
Individuals with greater lifetime use were more likely to be tired at the start of testing. 
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Table 5 also contains the correlations between the cognitive measures and the 
measures of illicit drug use. The data on which these are based have been reported by 
us previously although in the present paper we have combined data from a number of 
previous studies (Fisk et al 2004; 2005; Montgomery et al 2005a; 2005b; 2005c). As 
we reported previously, lifetime ecstasy use is significantly associated with 
impairments in executive functioning (computation span, word fluency), associative 
learning, and syllogistic reasoning. Higher lifetime levels of cannabis use are 
negatively associated with aspects of executive functioning (computation span) and 
learning. Similarly increased lifetime exposure to cocaine is significantly associated 
with reduced executive functioning (letter updating and word fluency) and impaired 
associative learning. Inspection of Table 5 also reveals that the use of illicit drugs 
during the previous 30 days is also significantly associated with impairments in 
aspects of cognitive functioning. However, for the most part the magnitude of the 
correlations is less than the equivalent ones with the total lifetime use measures. This 
is consistent with the proposition that it is longer term exposure which is responsible 
for the impairments that are noted. 
 
Discussion 
As reported by us previously, ecstasy users performed significantly worse than 
nonusers on various measures of executive functioning. Users of the drug had a 
greater percentage processing cost on the computation span test, recalled fewer letters 
correctly on the verbal updating task, supplied fewer correct words on the Chicago 
word fluency measure, were impaired on a paired associates learning task (poorer 
initial learning, more forgetting and longer to learn all associations) and performed 
significantly worse on the syllogistic reasoning task (although the user group by 
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difficulty interaction was non-significant). There were few differences observed in the 
sleep measures in the present study. No significant group differences were obtained 
on the ESS. On the Karolinska measures, while ecstasy users reported feeling more 
tired than nonusers at the beginning of testing, there was little difference in subjective 
tiredness at the end of testing. Contrary to expectations, inclusion of the sleep 
measures as covariates in the analyses did not attenuate the ecstasy-related deficits in 
the various aspects of cognition which remained statistically significant, the effect 
sizes virtually unchanged. 
Previous research in ecstasy users has found that users of the drug report 
disturbed sleep both as a primary subjective effect (Baylen & Rosenberg, 2006; 
Huxster et al. 2006; Montoya et al. 2002) and a longer lasting psychobiological 
complaint (Parrott et al. 2006). The present study found some support for sleep 
differences in ecstasy users. Ecstasy users began the test session significantly more 
tired than nonusers but reported little change throughout the test session. Nonusers on 
the other hand began the session less tired but experienced more incremental fatigue 
compared to users, over the testing session. Equal numbers of ecstasy users and 
nonusers were tested in the morning and afternoon sessions, so it is unlikely that the 
increased tiredness of ecstasy users prior to testing reflects straightforward time of 
day effects. 
Irregular patterns of wakefulness and sleep are more characteristic of young 
adult populations and especially student populations (Cole et al 2002). It is possible 
that the increased feeling of tiredness at the beginning of testing might reflect an 
inability among some ecstasy users to adjust their circadian clock. Studies on rats 
have revealed that MDMA and other serotonin-related drugs such as fenfluramine 
interfere with the animal’s ability to “reset” its circadian clock. The authors suggest 
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that this is due to serotonergic degeneration caused by ecstasy and fenfluramine 
(Biello and Dafters, 2001). This is further supported by Colbron et al. (2002) who 
found that repeated exposure to MDMA in hamsters altered the ability of the 
circadian clock to phase shift. These findings from animal studies are in line with 
research on human ecstasy users where “restless sleep” has frequently been cited as 
an effect of the drug (e.g. Huxster et al. 2006; Parrott et al. 2000; Parrott et al. 2006; 
Topp et al. 1999).   
It has been suggested that, in part, the cognitive deficits displayed by ecstasy 
users may reflect differences in lifestyle, for example it has been suggested that the 
lifestyle of an ecstasy user is one of constant circadian disruption, which has been 
responsible for similar cognitive deficits in aircrew (Cole et al, 2002). The present 
study does provide some evidence of increased tiredness among ecstasy users in that 
the initial scores on the Karolinska measure were reduced. However, the absence of 
ecstasy-related differences on the ESS is surprising and casts some doubt on Cole et 
al’s explanation of the cognitive deficits that have been observed in ecstasy users. In 
the present study, there was only limited evidence of sleep impairment and the 
inclusion of the sleep variables as covariates left the ecstasy-related effect sizes 
virtually unchanged with the group differences remaining significant.  
There were a number of significant correlations between drug use indices and 
sleep quality. There were significant correlations between the initial Karolinska 
measure and both total cannabis use and total ecstasy use indicating that those who 
had a greater lifetime exposure to ecstasy and cannabis reported poorer sleep. The 
ESS was also significantly correlated with the Karolinska measure at the end of the 
test session in that those who were most tired at the end of the session tended to score 
higher on the ESS. The drug use indicators were also found to be correlated with the 
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cognitive measures in that higher levels of use were associated with cognitive 
impairment. However, caution is needed in interpreting the correlations set out in 
Table 5. Since the majority of ecstasy users also used cannabis and cocaine, the 
possibility that the drugs interact in some way to produce their effects cannot be ruled 
out. Furthermore, virtually all of the cocaine users were also ecstasy users so the 
significant correlations do not imply a simple direct relationship between cocaine use 
and cognitive outcomes. 
Taken as a whole the results of the present study provide tentative support for 
one of the propositions made in the introduction. Three possible ecstasy-sleep-
cognition relationships were proposed. Ecstasy-related deficits were observed in the 
various cognitive measures that were administered. There were also some differences 
in one of the sleep measures. However, little evidence was found for the mediating 
effects of sleep on cognitive deficits in ecstasy users. Consequently, as suggested in 
the introduction, it may be that ecstasy users exhibit impaired sleep quality, and 
impaired cognition, but the two are not related.  
There were a number of limitations with the present study. Firstly, due to 
limited resources we had to rely on self-reports of previous drug use. Other studies 
have also relied on self-report measures of ecstasy use (e.g. Fox et al. 2002; Morgan 
1998; Morgan 1999; Rodgers 2000). Nonetheless while the questionnaire we used has 
numerous checks for internal consistency and while we have no reason to doubt the 
responses of our participants, it would have been more desirable to supplement the 
self reports with objective measures of recent use (e.g. from urine or hair samples). 
Second, we used self report measures of sleep quality and it is possible that other 
more objective measures such as polysomnography might demonstrate that ecstasy 
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users do exhibit altered sleep patters and that these are related in some way to the 
cognitive impairments that have been observed.  
Serotonergic neural pathways are known to be involved in sleep regulation 
and both directly and indirectly affect the integrity of cognitive processes. A corollary 
of this is that deficient brain serotonin activity is believed to be associated with sleep 
abnormalities, which in turn promote behavioral decline, psychiatric disorders, and 
deficiencies in the regulation of affective states (Markus et al, 2005; Voderholzer et 
al, 1998). Much of the research investigating the role of serotonin in sleep regulation 
has utilised polysomnography to explore the effects of manipulating the availability of 
the serotonin precursor tryptophan. Increasing its availability just before bedtime has 
been found to reduce feelings of sleepiness the following morning, enhance the 
capacity for sustained attention, and in poor sleepers enhance the speed of responding 
and reduce errors in a reaction time task (Markus et al, 2005). By way of contrast, 
tryptophan depletion led to increased wakefulness, decreased stage 2 sleep, and 
significant alterations in aspects of REM sleep, highlighting the important role of the 
serotonergic system in sleep maintainance and regulation (Huwig-Poppe et al, 1999; 
Voderholzer et al, 1998). Given that there is considerable evidence indicating reduced 
levels of serotonergic activity in abstinent ecstasy users (McCann et al 2000), future 
research might utilise the tryptophan challenge approach in order to accentuate and 
render more transparent the role that sleep disturbance might play in underpinning the 
ecstasy-related cognitive deficits that have been observed.  
In conclusion while ecstasy users exhibited differences on some sleep 
measures these did not appear to mediate the cognitive deficits that were observed. 
Future research utilising more objective measures of sleep quality as well as 
pharmacological interventions might further clarify the extent to which sleep 
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impairments are responsible for the cognitive deficits that have been observed in 
ecstasy users. 
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Table 1. Age, Years of Education, Intelligence, and Measures of Illicit Drug Use
A
 for Current 
and Previous Users for those Participants Completing the Epworth Sleepiness Scale and the 
Background Sleep Attributes Questions 
 Ecstasy Users Non Ecstasy Users T
B
 
 Mean S.D. n Mean S.D. n  
Age 21.68 1.96 104 21.11 1.66 103  2.29* 
Ravens Progressive Matrices 47.77 6.15 102 48.53 5.31 102  0.35 
NART 28.48 6.52 104 29.58 5.38 102  0.19 
Ecstasy        
Lifetime dose (tablets) 349.97 464.41 104 - - -  
Current use (tablets taken in 
previous 30 days) 
3.19 4.95 103 - - -  
     Weeks since last use  
     (mean/median) 
19.35 (3) 43.46 104 - - -  
Cannabis        
Lifetime dose (joints) 3406.37 4710.24 80 763.10 1163.55 37  4.72*** 
Current use (joints taken in 
previous 30 days) 
40.34 64.19 79 9.30 25.84 35  3.68*** 
     Weeks since last use  
     (mean/median) 
21.01 (0.43) 73.91 91 24.06 (3.50) 56.36 56 -0.27 
Cocaine        
Lifetime dose (grams) 48.60 78.91 40 - - 0  
Current use (grams taken in 
previous 30 days) 
1.52 1.98 38 - - 0  
     Weeks since last use  
     (mean/median) 
14.99 (3) 38.49 82 41.33 (8) 68.23 9 -1.14 
Amphetamine        
Lifetime dose (grams) 77.46 140.12 31 4.00 - 1  
Current use (grams taken in 
previous 30 days) 
0.36 1.31 21 - - 0  
     Weeks since last use  
     (mean/median) 
96.29 (46) 117.96 42 208.00 (260) 90.07 3  
 
*** p<.001; ** p<.01; * p<.05 
 
Note A: The estimate of weeks since last use includes individuals who have used the 
drug in question on relatively few or on just a single occasion. Some individuals, 
especially infrequent users were unable to provide estimates for lifetime dose or 
current use. 
 
Note B: t is calculated only where there are at least nine participants in each group
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Table 2. Indicators of daytime sleepiness among ecstasy users and nonusers 
 
 
 Ecstasy Users Nonusers Mann-Whitney U / t test 
 25
th
 
Percentile 
Median 75
th
 
Percentile 
25
th
 
Percentile 
Median 75
th
 
Percentile 
 
Epworth Daytime Sleepiness 
(maximum 24) 
4 6 8 4 6.5 9 U = 4709.5,  p >.05 
Karolinska Sleepiness Scale 
(maximum 9; mean/standard 
deviation) 
      First Administration 
  
 
4.90 
 
 
1.49 
  
 
4.37 
 
 
1.57 
 
 
t = 2.01, p<.05 
      Second Administration  5.52 1.58  5.71 1.53 t = -0.71,  p >.05 
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Table 3. Age, Years of Education, Intelligence, and Measures of Illicit Drug Use for Current 
and Previous Users for those Participants Completing the Karolinska Sleepiness Scale 
  Ecstasy Users Non Ecstasy Users T
B
 
 Mean S.D. n Mean S.D. n  
Age 21.72 2.04 69 20.86 1.47 63  2.82** 
Ravens Progressive Matrices 47.24 6.11 67 48.70 5.45 63 -1.43 
NART 28.41 6.23 69 28.53 5.14 62 -0.13 
Ecstasy
 A
        
Lifetime dose (tablets) 337.40 493.26 69 - - -  
Current use (tablets taken 
in previous 30 days) 
2.45 3.36 69 - - -  
     Weeks since last use  
     (mean/median) 
24.24 (3) 49.37 69 - - -  
Cannabis
 A
        
Lifetime dose (joints) 2830.18 4003.98 55 558.00 1012.21 25  3.94*** 
Current use (joints taken 
in previous 30 days) 
34.75 55.18 55 9.98 30.78 24  2.54* 
     Weeks since last use  
     (mean/median)
 
 
27.92 (0.43) 87.50 61 30.89 (6) 65.18 40 -0.18 
Cocaine
 A
        
Lifetime dose (grams) 52.40 85.37 25 - - 0  
Current use (grams taken 
in previous 30 days) 
0.73 0.84 25 - - 0  
     Weeks since last use  
     (mean/median)
 
 
18.31 (3) 46.78 53 59.00 (30) 79.46 6  
Amphetamine
 A
        
Lifetime dose (grams) 77.57 120.36 19 - - 0  
Current use (grams taken 
in previous 30 days) 
0.10 0.27 16 - - 0  
     Weeks since last use  
     (mean/median)
 
 
117.13 (54) 136.71 24 182.00 (182) 110.31 2  
 
*** p<.001; ** p<.01; * p<.05 
 
Note A: The estimate of weeks since last use includes individuals who have used the 
drug in question on relatively few or on just a single occasion. Some individuals, 
especially infrequent users were unable to provide estimates for lifetime dose or 
current use. 
 
Note B: t is calculated only where there are at least nine participants in each group 
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Table 4. Executive Functioning, Associative Learning and Reasoning Outcomes for 
Ecstasy/polydrug Users and Nonusers 
 
 Ecstasy Users Non Ecstasy Users 
 Mean S.D. n Mean S.D. n 
Computation Span  
(% processing cost) 
43.46 24.86 104 31.23 22.31 103 
Consonant Updating 
(maximum six) 
2.16 0.49 29 2.46 0.53 35 
Word Fluency       
      Chicago Word Fluency  
      (standardised score) 
-0.40 0.84 36 0.23 0.86 63 
      Semantic Fluency  
      (standardised score) 
-0.17 0.94 36 0.10 1.03 63 
Paired Associate Learning       
      Trials to Completion 5.63 1.65 30 4.32 1.43 63 
      Initial Learning 3.17 2.02 30 4.32 1.99 63 
      Forgetting 0.83 0.87 30 0.46 0.91 63 
Syllogistic Reasoning       
      One Model 3.78 1.96 32 4.92 1.86 51 
      Two/Three Model 1.31 1.82 32 1.76 1.62 51 
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Table 5 Correlations (Spearman’s ρ) between aspects of cognitive functioning, 
daytime sleepiness and measures ecstasy use
A
. 
 
 Epworth 
Sleepiness 
Measure 
    Ecstasy          Cannabis           Cocaine 
        
  Total 
lifetime 
use 
Current 
use
B
 
Total 
lifetime 
use 
Current 
use
B
 
Total 
lifetime use 
Current 
use
B
 
Computation Span  
(Percentage cost) 
 .019 
n=206 
 .239** 
n=207 
 .116 
n=206 
.185* 
n=172 
.176* 
n=193 
.220** 
n=154 
.108 
n=182 
Consonant Updating 
 
 .007 
n=63 
-.201 
n=64 
-.166 
n=63 
-.214 
n=53 
-.068 
n=59 
-.289* 
n=49 
-.206* 
n=56 
Chicago Word Fluency  
 
-.163 
n=98 
-.358** 
n=99 
-.293** 
n=98 
-.189 
n=80 
-.178 
n=92 
-.400** 
n=79 
-.312** 
n=90 
Paired Associate 
Learning 
       
      Trials to Completion  .025 
n=92 
 .370** 
n=93 
 .286** 
n=92 
.205 
n=75 
.245* 
n=86 
.404** 
n=75 
.225* 
n=84 
      Initial Learning -.148 
n=92 
-.318** 
n=98 
-.150 
n=97 
-.334** 
n=75 
-.365** 
n=89 
-.299** 
n=78 
-.232* 
n=88 
      Forgetting 
 
-.078 
n=92 
 .318** 
n=98 
 .216* 
n=97 
.192 
n=75 
.182 
n=89 
.316** 
n=78 
.232* 
n=88 
Syllogistic Reasoning        
      One Model -.137 
n=82 
-.259* 
n=83 
-.137 
n=82 
-.056 
n=62 
-.086 
n=75 
-.174 
n=71 
-.204 
n=77 
      Two/Three Model -.115 
n=82 
-.143 
n=83 
-.001 
n=82 
-.053 
n=62 
-.004 
n=75 
.020 
n=71 
.093 
n=77 
        
Epworth Sleepiness 
Scale 
     - -.091 
n=203 
-.161* 
n=202 
-.100 
n=169 
-.075 
n=190 
-.089 
n=151 
-.063 
n=178 
Karolinska  
      (start of session) 
-.001 
n=132 
 .260** 
n=132 
 .125 
n=132 
.247** 
n=110 
.079 
n=123 
.126 
n=96 
.158 
n=116 
Karolinska  
      (end of session) 
 .344** 
n=132 
-.059 
n=132 
 .043 
n=132 
-.007 
n=110 
-.061 
n=123 
-.010 
n=96 
-.012 
n=116 
 
*** p<.001; ** p<.01; * p<.05 
 
Note A: With regard to the total and current use estimates, scores for nonusers are 
entered as zero. Some participants were unable to estimate their pattern of use.  
 
Note B: Current use refers to the amount consumed during the previous 30 days. 
